Physician profile
Danni P Gray
NPI 1124659495
$574.90
in general payments reported to CMS, 2019-2025
15 companies · $61.79 in 2025
The $61.79 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $142 · 2022: $38.53 · 2023: $123 · 2024: $210 · 2025: $61.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $120.22 | 2021-2024 | |
| Amgen INC. | $102.33 | 2021-2024 | Repatha |
| Novo Nordisk INC | $89.83 | 2023-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $34.89 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.89 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
| Spinal Simplicity, LLC | $24.46 | 2025 | Ha Minuteman G3-R |
| Exeltis, USA INC. | $22.92 | 2023 | Slynd |
| Xeris Pharmaceuticals, INC. | $22.53 | 2022 | |
| Astellas Pharma US INC | $21.47 | 2025 | Veozah |
| Lilly USA, LLC | $20.38 | 2024 | Jardiance |
| Dynavax Technologies Corporation | $19.65 | 2024 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $17.71 | 2023 | Farxiga |
| Exact Sciences Corporation | $16.49 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $16.00 | 2022 | |
| Therapeuticsmd, INC. | $15.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danni Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.